Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
RLF-OD032 demonstrated bioequivalence to KUVAN® PowderStudy results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire...